Depression: all studies (page 340) - The Consciousness Library

The Mediating Role of Mindfulness and Self-Compassion in the Link between Tinnitus Distress and Anxiety.

Audiology & neuro-otology March 12, 2026 Weronika Caban, Paweł Holas, Mikołaj Kuncewicz et al.

Introduction: Tinnitus is the perception of sound in the absence of external stimuli, often experienced as ringing or buzzing. While many individuals habituate to tinnitus, others develop chronic tinnitus (CT), which can severely affect emotional well-being. Psychological mechanisms such as anxiety and maladaptive coping are known contributors to tinnitus distress, yet the protective role of...

DOI: 10.1159/000550912 Depression Anxiety Mindfulness Humans +9

Mindfulness-based stress reduction for patients with coronary heart disease and bipolar disorder: An 8-week comparative study.

Cambridge Prisms Global Mental Health March 10, 2026 Jiawei Wang, Yechen Wu, Fan Yang et al.

Coronary heart disease (CHD) often coexists with mood disorders (MDs), but research on comorbidity predictors and interventions remains limited. This two‑phase mixed‑methods study enrolled 390 CHD patients diagnosed by coronary angiography. Mood disorders were screened using the HAMD (≥7) and confirmed via DSM‑5 psychiatric evaluation. In the observational phase, 219 CHD patients with MDs and...

DOI: 10.1017/gmh.2026.10143 Full text Depression Mental health Bipolar disorder Coronary heart disease +3

Enhancing cGMP signaling with psilocybin reduces head twitch and restructures the synaptic proteome while maintaining antidepressant response

bioRxiv (Cold Spring Harbor Laboratory) March 10, 2026 Gabriele Floris, Sarah J. Jefferson, Jocelyne Rondeau et al. preprint

Abstract New treatments for depression are needed that combine robust efficacy with improved scalability. Although psilocybin has demonstrated antidepressant effects in Phase 3 clinical trials, some of its psychedelic effects limit tolerability, necessitating administration in highly supervised clinical settings, and thus motivating development of serotonergic therapeutics that preserve...

DOI: 10.64898/2026.03.06.710108 Full text Psilocybin Serotonergic Treatment-resistant depression Antidepressant +3

Brain functional network correlates and predictors of the perioperative antidepressant effect of esketamine in breast cancer patients: a double-blind randomized controlled trial using resting-state fMRI and graph theory.

Translational Psychiatry March 6, 2026 Huimin Zhu, Qingfeng Wei, Shuang Xu et al. 1 citation

Postoperative depression adversely influences breast cancer patients' clinical outcomes. Our prior study demonstrated that intraoperative esketamine ameliorated postoperative depression in breast cancer patients, yet the underlying neural mechanism remains incompletely understood. We performed a double-blind randomized controlled trial in 35 breast cancer patients with preoperative depressive...

DOI: 10.1038/s41398-026-03929-3 Full text Ketamine Depression Brain Humans +9

Ketamine as an NMDA-modulating therapy in bipolar disorder: rationale and evidence

Frontiers in Psychiatry March 4, 2026 Robert Queissner, F. Fellendorf, E. Z. Reininghaus

Background Bipolar depression remains a leading cause of morbidity, functional impairment, and suicide risk in bipolar disorder. Conventional pharmacotherapies often provide delayed or incomplete relief and may increase the risk of treatment-emergent affective switching. Recent evidence highlights the therapeutic potential of NMDA receptor antagonists, particularly ketamine and its S-enantiomer...

DOI: 10.3389/fpsyt.2026.1777402 Ketamine Treatment-resistant depression Major depressive disorder Bipolar disorder +9

Cannabis vaping and mental health: The association of Δ-9-tetrahydrocannabinol and cannabidiol with anxiety and depressive symptoms-Findings from the United States National Youth Tobacco Survey (2021-2023).

Addiction March 2026 Jack Chung, Daniel Stjepanović, Brandon Cheng et al.

Cannabis use is associated with psychiatric comorbidities, and the use of elta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) produces different neurophysiological and pharmacological effects. This study estimated the strength of associations between vaping of THC and CBD with depressive and anxiety symptoms in adolescents. Observational data were drawn from three years of the nationally...

DOI: 10.1111/add.70218 Full text Anxiety Depression Cannabis use Mental health +1

A Blueprint for Implementing Ketamine-Assisted Psychotherapy in Palliative Care: Design, Process, and Treatment Patterns of a Real-World Clinical Program.

Journal of Palliative Medicine March 1, 2026 Robert K Horowitz, William E Rosa, Ali John Zarrabi et al.

Psychospiritual distress (PSD) causes profound suffering in people with serious illness, yet treatment options are few and evidence of their efficacy is modest. Although high-level evidence is limited, decades of preliminary research suggest that psychedelic-assisted psychotherapy (PAP), including ketamine-assisted psychotherapy (KAP), may alleviate the anxiety, depression, and existential...

DOI: 10.1177/10966218251392787 Full text Anxiety Depression Existential distress Psychedelic-assisted psychotherapy +5

A scoping review of mystical-type experiences and mood symptom outcomes in psychedelic therapy clinical trials: comparing life-threatening disease and depressive populations

Therapeutic Advances in Psychopharmacology March 1, 2026 Ana Deutsch, Luis E. Contreras, Sarah Kratina et al.

Background: Psychedelic therapies are gaining attention as tools to alleviate anxiety and depression across various clinical populations. However, the mechanisms behind psychedelics' therapeutic efficacy and the potential differences in how patients with certain diagnoses experience their subjective effects remain unknown. One commonly suggested mediator of positive outcomes across psychedelics...

DOI: 10.1177/20451253261433836 Anxiety Major depressive disorder Psilocybin Psycinfo +8

Effects of Intraoperative Esketamine–Dexmedetomidine Combination on Postpartum Depressive Symptoms and Neuropsychiatric Events Following Cesarean Delivery: A Randomized Controlled Trial

Drug Design, Development and Therapy March 1, 2026 Meng-Meng Li, Qingfeng Wei, Qian-Yun Zhu et al.

Combined low-dose dexmedetomidine and esketamine during cesarean section provides a short-term improvement in early postpartum depressive symptoms, reduces intraoperative neuropsychiatric adverse events, and enhances maternal satisfaction, with a favorable maternal and neonatal safety profile.

DOI: 10.2147/dddt.s587487 Major depressive disorder Dexmedetomidine Adverse effect Randomized controlled trial +11

Ketamine and Esketamine Therapy in Affective Disorders: A Comprehensive Review of Mechanisms, Clinical Evidence, Safety, and Future Directions

Zenodo (CERN European Organization for Nuclear Research) February 28, 2026 Kshirsagar Pankaj*, Misal Shivdarshan, Dr. Giri Ashok preprint

Major Depressive Disorder (MDD) and Bipolar Depression represent significant global health burdens because about one-third of patients who receive standard monoaminergic antidepressant treatment fail to achieve remission. The population with Treatment-Resistant Depression (TRD) needs assistance because they deal with dangerous suicide risks and struggle with their daily activities. The review...

DOI: 10.5281/zenodo.18817380 Ketamine Treatment-resistant depression Major depressive disorder Suicidal ideation +9